drugset / Trial / NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Timeline
- Start
- 2025-04-02
- Primary completion
- 2028-06-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Firmonertinib | Small molecule | 80 mg | — |
| Subject | Firmonertinib | Small molecule | 160 mg | — |
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |